NCT00805740

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.

Conditions

• Candidiasis
• Fungemia

Interventions

Type	Name	Description
DRUG	Active anidulafungin	Subjects in this arm will receive active anidulafungin and placebo caspofungin
DRUG	Active Caspofungin	Subjects in this arm will receive active caspofungin and placebo anidulafungin

Timeline

• Start date: 2009-04-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2008-12-10
• Last updated: 2013-08-01
• Results posted: 2013-08-01

Locations

18 sites across 9 countries: United States, Belgium, Bulgaria, Canada, Netherlands, Portugal, Romania, Russia, Switzerland